Patents Assigned to Schepens Eye Research Institute
  • Patent number: 11896522
    Abstract: A device includes a frame, a rotatable housing and a permanent magnet. The frame is configured to be worn adjacent an eye region of a wearer. The rotatable housing is coupled to the frame. The permanent magnet is coupled to the rotatable housing and includes a first surface having a first static magnetic polarity and a second surface having a second static magnetic polarity opposite the first static magnetic polarity. The rotatable housing is arranged to rotate the permanent magnet between a first position orienting the first surface towards the eye region of the wearer and a second position orienting the second surface towards the eye region of the wearer. Related apparatus, systems, techniques and articles are also described.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 13, 2024
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Kevin Houston, Eleftherios Paschalis Ilios, Matteo Tomasi
  • Patent number: 11759499
    Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: September 19, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Sunil Chauhan, Reza Dana
  • Patent number: 11739326
    Abstract: The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: August 29, 2023
    Assignees: Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.
    Inventors: Leo A. Kim, Joseph F. Arboleda-Velasquez, Dhanesh Amarnani, Dean Eliott
  • Publication number: 20230242940
    Abstract: Provided herein are vaccines against coronavirus that utilize adeno-associated virus (AAV) for delivery.
    Type: Application
    Filed: April 13, 2021
    Publication date: August 3, 2023
    Applicants: Massachusetts Eye and Ear Infirmary, The Schepens Eye Research Institute, Inc.
    Inventors: Luc H. Vandenberghe, Urja Achal Bhatt, Nerea Zabaleta Lasarte, Wenlong Dai
  • Patent number: 11692029
    Abstract: The invention provides compositions and methods for treating optic neuropathic disorders.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: July 4, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Ji Min, Kin-Sang Cho, Dong Feng Chen
  • Publication number: 20230190959
    Abstract: The present subject matter provides, inter alia compositions, formulations, and methods for inhibiting, treating, and preventing small vessel diseases.
    Type: Application
    Filed: March 26, 2018
    Publication date: June 22, 2023
    Applicant: The Schepens Eye Research Institute, Inc.
    Inventor: Joseph F. Arboleda-Velasquez
  • Patent number: 11680266
    Abstract: A method for reducing neovascularization in an ocular tissue is carried out by contacting the tissue with an inhibitor of endomucin expression or activity.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: June 20, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Patricia A. D'Amore, Magali Saint-Geniez, Cindy Park-Windhol
  • Patent number: 11622951
    Abstract: The invention provides compositions and methods for preserving, restoring, or enhancing vision of a subject by administering compositions to an injured or diseased eye.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: April 11, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Dong Feng Chen, Kin-Sang Cho
  • Patent number: 11594308
    Abstract: Methods and systems providing adaptive assessment of a physical subject to efficiently collect assessment data and modify an assessment schedule based on the analyses. The methods and systems can control the timing of each assessment in order to collect data at times and under conditions that are most informative about the physical subject. Such adaptive methods and systems significantly minimize the frequency of data collection without loss in accuracy or precision and can increase test reliability through reduction in redundancy. The ability to estimate an unknown, underlying function using a small number of free parameters that remain constant regardless of the number of data points being estimated substantially reduces the error of the function estimate. Because estimates of the measurement error are achieved with a minimum of sampled assessments, and with great accuracy, the statistical power of clinical trials, for example, can be greatly increased.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 28, 2023
    Assignees: NORTHEASTERN UNIVERSITY, THE SCHEPENS EYE RESEARCH INSTITUTE, INC.
    Inventors: Peter John Bex, John F. Ackermann, Tobias Elze
  • Patent number: 11583497
    Abstract: The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBF?-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: February 21, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Leo A. Kim, Joseph F. Arboleda-Velasquez
  • Patent number: 11554048
    Abstract: Systems and methods of treating meibomian and sebaceous gland dysfunction. The methods include reducing oxygen concentration in the environment of one or more dysfunctional meibomian and sebaceous glands, thereby restoring a hypoxic status of one or more dysfunctional meibomian and sebaceous glands. The reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian and sebaceous glands and the environment of one or more dysfunctional meibomian sebaceous glands. The restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian or sebaceous glands. The methods also include giving local or systemic drugs that lead to the generation of hypoxia-inducible factors in one or more dysfunctional meibomian and sebaceous glands.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: January 17, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: David A. Sullivan, Yang Liu
  • Patent number: 11554104
    Abstract: The disclosure relates to compositions containing allyl isothiocyanate and methods of use thereof for stimulating tearing in a subject to treat dry eye.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 17, 2023
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventor: Joseph B. Ciolino
  • Patent number: 11520169
    Abstract: An implementation of an optical system for expanding the field of view can include a first optical element and a second optical element. The first optical element can include a first surface and a second surface. The first surface can be configured to reflect a first light beam incident on the first surface at a first incident angle greater than a first predetermined angle, and the second surface can be configured to reflect the reflected first light beam towards a location. The second optical element can include a third surface and a fourth surface. The third surface can be configured to reflect a second light beam incident on the third surface at a second incident angle greater than a second predetermined angle, and the fourth surface can be configured to reflect the reflected second light beam towards the location. Related apparatus, systems, techniques and articles are also described.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: December 6, 2022
    Assignees: THE SCHEPENS EYE RESEARCH INSTITUTE, INC., THE UNIVERSITY OF MURCIA
    Inventors: Eliezer Peli, Fernando Vargas-Martin
  • Patent number: 11466258
    Abstract: Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: October 11, 2022
    Assignees: The Schepens Eye Research Institute, Inc., Massachusetts Eye and Ear Infirmary
    Inventors: Luk H. Vandenberghe, Eric Zinn
  • Patent number: 11464773
    Abstract: The invention provides compositions and methods for treatment of proliferative vitreoretinopathy.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: October 11, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventor: Andrius Kazlauskas
  • Patent number: 11453718
    Abstract: The present subject matter provides, inter alia compositions, formulations, and methods for inhibiting, treating, and preventing small vessel diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: September 27, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventor: Joseph F. Arboleda-Velasquez
  • Patent number: 11351225
    Abstract: The present invention relates to compositions and methods comprising administering gene modifiers for treating ocular disease.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: June 7, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventor: Neena B. Haider
  • Publication number: 20220118024
    Abstract: Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface.
    Type: Application
    Filed: September 27, 2021
    Publication date: April 21, 2022
    Applicants: The United States of America as represented by the Department of Veterans Affairs, Schepens Eye Research Institute, Children's Medical Center Corporation
    Inventors: Markus H. Frank, Natasha Y. Frank, Bruce Ksander, Paraskevi Evi Kolovou
  • Patent number: 11306140
    Abstract: Methods and compositions for reducing the activity or number of memory Th17 cells in ocular tissue, and for treatment and/or prevention of ocular immunoinflammatory diseases are described.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 19, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Sunil Chauhan, Yihe Chen
  • Patent number: 11301993
    Abstract: The current subject matter relates to rehabilitation using a content guide for viewing video, for example as a vision rehabilitation aid for individuals with hemianopia or as a rehabilitation aid for individuals with attention disorders. The current subject matter includes providing video in which a region of interest of the image is specified with a marker, referred to herein as a content guide. The content guide can include a circle surrounding the region of interest. By providing video with a content guide to direct viewers to a region of interest in the video, information acquisition by the viewers is improved. Such an approach can aid individuals with vision deficits or attention disorders. The current subject matter can also be used as a therapy for spatial neglect. Related apparatus, systems, techniques and articles are also described.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: April 12, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Dylan J. Rose, Daniel R. Saunders, Russell L. Woods